This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

This study has been completed.
Centocor, Inc.
Information provided by (Responsible Party):
Neil Korman, University Hospitals Cleveland Medical Center Identifier:
First received: November 13, 2008
Last updated: September 27, 2016
Last verified: September 2016

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum.

This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

Condition Intervention
Pyoderma Gangrenosum Crohn's Disease Ulcerative Colitis Inflammatory Bowel Disease Drug: Infliximab

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum

Resource links provided by NLM:

Further study details as provided by Neil Korman, University Hospitals Cleveland Medical Center:

Primary Outcome Measures:
  • The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease [ Time Frame: Week 26 ]
    Outcome was measured by clinical assessment of pyoderma gangrenosum. The number of patients who had improvement and/or clearance of the pyoderma grangrenosum after the infusions and through the follow up visit was assessed.

Enrollment: 2
Study Start Date: October 2008
Study Completion Date: February 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Infliximab
Single arm open label IV Infliximab given at weeks 1,2,14,22
Drug: Infliximab
IV drug given at weeks 1,2,14,22
Other Name: Remicade


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must Be ages 18-75
  • Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum
  • Must never have received Infliximab for the treatment of pyoderma gangrenosum

Exclusion Criteria:

  • Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.
  • Have a history of serious infections
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00791557

United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Centocor, Inc.
Principal Investigator: Neil J Korman, MD.PhD University Hospitals Cleveland Medical Center
  More Information

Responsible Party: Neil Korman, Principle Investigator, University Hospitals Cleveland Medical Center Identifier: NCT00791557     History of Changes
Other Study ID Numbers: 06-07-14
Study First Received: November 13, 2008
Results First Received: September 3, 2013
Last Updated: September 27, 2016

Additional relevant MeSH terms:
Crohn Disease
Colitis, Ulcerative
Intestinal Diseases
Inflammatory Bowel Diseases
Pyoderma Gangrenosum
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Skin Diseases
Skin Diseases, Vascular
Skin Ulcer
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents processed this record on August 18, 2017